Microdosing GLP-1 is the use of very small, gradual doses of compounded injectable semaglutide or tirzepatide. This approach may offer overall wellness and healthy aging benefits while potentially reducing the likelihood and severity of side effects.

No. Microdose GLP-1 is often explored for longevity-focused support beyond weight loss, including metabolic health and overall wellness.

Microdose GLP-1 uses lower doses than standard protocols. This gentler approach prioritizes tolerability and long-term metabolic support rather than aggressive short-term outcomes.

Microdose GLP-1 may be an option for adults interested in supporting overall wellness, healthy aging, or metabolic health with a gentler approach than standard GLP-1 doses. It may be considered for individuals who are sensitive to higher doses or want to potentially minimize side effects. Your provider can help determine if microdosing is appropriate based on your health history and goals.

Because Microdose GLP-1 uses a lower dose of semaglutide or tirzepatide, it may be associated with a lower likelihood and severity of side effects compared to standard doses. Possible side effects are expected to be similar to other semaglutide or tirzepatide medications and can include nausea, diarrhea, constipation, abdominal pain, headache, and fatigue. Most side effects are temporary and may resolve within a few days to a few weeks. If they persist or worsen, contact your provider.